Evaluation of the efficacy of radiofrequency ablation therapy in cases with parathyroid adenoma

Basit Öğe Kaydı
dc.contributor.authorEvren, Bahri
dc.contributor.authorBozbay, Abdulkadir
dc.contributor.authorYildirim, Ismail Okan
dc.contributor.authorTopaloglu, Omercan
dc.contributor.authorSahin, Ibrahim
dc.date.accessioned2026-04-04T13:30:42Z
dc.date.available2026-04-04T13:30:42Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground/aim: Radiofrequency ablation of solitary parathyroid adenoma has been used to treat primary hyperparathyroidism (pHPT) in high-risk patients for parathyroidectomy. This study aimed to evaluate the clinical efficacy of radiofrequency ablation for treating pHPT in patients with parathyroid adenomas. Materials and methods: The sample for this retrospective study comprised all consecutive patients with solitary parathyroid adenoma treated with radiofrequency ablation between 2013 and 2021. Patients' baseline serum calcium and parathyroid hormone (PTH) values were obtained. The patients were followed up with serial biochemical measurements after the intervention, then at the first-week, first-month, third-month, sixth-month, and twelfth-month follow-ups. The study's primary outcome was a biochemical cure, defined as the reestablishment of normal serum calcium and PTH levels, persisting for at least 6 months after the ablation. Results: The changes in the serum calcium and PTH levels were significant (p < 0.05). The biochemical cure rate was 30.2% at 1 year. At the end of 1 year, the rate of patients with normal serum calcium levels was 86.6%, whereas the rate of patients with normal serum calcium and higher PTH levels was 55.8%. Conclusion: Radiofrequency ablation of a solitary parathyroid adenoma may be considered an alternative treatment for pHPT, given that more than half of the cases investigated in this study had normocalcemic hyperparathyroidism at 1 year.
dc.identifier.doi10.55730/1300-0144.6108
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue6
dc.identifier.pmid41509929
dc.identifier.scopus2-s2.0-105027081141
dc.identifier.scopusqualityQ2
dc.identifier.trdizinid1393373
dc.identifier.urihttps://doi.org/10.55730/1300-0144.6108
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1393373
dc.identifier.urihttps://hdl.handle.net/11616/108313
dc.identifier.volume55
dc.identifier.wosWOS:001667769600016
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectPrimary hyperparathyroidism
dc.subjectparathyroid adenoma
dc.subjectradiofrequency ablation
dc.subjecthypercalcemia
dc.titleEvaluation of the efficacy of radiofrequency ablation therapy in cases with parathyroid adenoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu